A study evaluating CAM2058 for the prevention and treatment of postoperative pain, nausea and vomiting.

Trial Profile

A study evaluating CAM2058 for the prevention and treatment of postoperative pain, nausea and vomiting.

Planning
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Buprenorphine/granisetron (Primary)
  • Indications Postoperative nausea and vomiting; Postoperative pain
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2016 New trial record
    • 24 Oct 2016 According to a Braeburn Pharmaceuticals media release, company is planning clinical development of CAM2058 during the fourth quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top